Novartis trims its pipeline
Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.
Fate runs out of excuses
The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.
Your 2023 wildcard predictions revealed
Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.
Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
GSK’s “crown jewels” already look tarnished
As the company pulls Blenrep, questions about its future will only intensify.
Pulling back the curtain on Astrazeneca’s Car-T work
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.
